Latest Articles about OGXI

OncoGenex Loss Lower than Expected - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 23:26:28 Z

OncoGenex Pharmaceuticals, Inc. ( OGXI ) reported first quarter 2013 net loss per share of 46 cents, narrower than the Zacks Consensus Estimate of a loss of 68 cents and the year-ago loss

OncoGenex' OGX-427 Progresses - Analyst Blog

Zacks Equity Research — Sat, 13 Apr 2013 01:08:04 Z

OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Spruce, for the potential treatment of

OncoGenex Loss Lower than Expected - Analyst Blog

Zacks Equity Research — Tue, 12 Mar 2013 00:09:37 Z

OncoGenex Pharmaceuticals, Inc. ( OGXI ) reported fourth quarter 2012 net loss per share of 39 cents, narrower than the Zacks Consensus Estimate of a loss of 49 cents and the year-ago loss

OncoGenex' Candidate Progresses - Analyst Blog

Zacks Equity Research — Fri, 15 Feb 2013 02:50:01 Z

OncoGenex Pharmaceuticals, Inc. ( OGXI ) recently announced that it is looking to move its oncology candidate, OGX-427, into a phase II study, Borealis-2, for the potential treatment of

Isis Pharma Updates on its Pipeline - Analyst Blog

Zacks Equity Research — Sat, 12 Jan 2013 01:20:01 Z

Isis Pharmaceuticals, Inc. ( ISIS ) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The company believes 5 of its pipeline candidates can get approval

The Cancer Conference Trade: Picking Up Biotech Bargains

Kapitall — Fri, 22 Jul 2011 01:23:55 Z

( List compiled by Alexander Crawford ) Biotech stocks as a whole tend to underperform after the annual American Society of Clinical Oncology (ASCO) conference in June. Many investors buy

The Value Play Backed by 150 Patents

David Sterman — Tue, 12 Jan 2010 22:38:28 Z

You could take a stab at Medivation, Inc. (Nasdaq: MDVN) , whose progress on Alzheimer's treatment has sent its shares soaring three-fold since March. But then there's OncoGenix